Piracetam-d6 | CAS#unknown | Piracetam internal standard

MedKoo Cat#: 465309 | Name: Piracetam-d6

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Piracetam-d6 is intended for use as an internal standard for the quantification of piracetam by GC- or LC-MS. Piracetam is a nootropic cyclic GABA derivative. It is a positive allosteric modulator of AMPA receptors and enhances binding of the NMDA antagonist MK-801 to rat forebrain membranes. Piracetam (1 mM) protects against amyloid-β-induced decreases in the mitochondrial membrane potential, as well as decreases in neurite outgrowth in the presence of NGF, in PC12 rat adrenal medulla cells. It prevents scopolamine-induced amnesia in a passive avoidance test in mice when administered at a dose of 30 mg/kg. Formulations containing piracetam have been used in the treatment of myoclonus.

Chemical Structure

Piracetam-d6

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465309

Name: Piracetam-d6

CAS#: unknown

Chemical Formula: C6H4D6N2O2

Exact Mass: 148.1119

Molecular Weight: 148.19

Elemental Analysis: C, 48.63; H, 10.88; N, 18.90; O, 21.59

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 550.00	2 Weeks
5mg	USD 1,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Piracetam-d6; Piracetam d6;

IUPAC/Chemical Name

2-(2-oxopyrrolidin-1-yl-3,3,4,4,5,5-d6)acetamide

InChi Key

GMZVRMREEHBGGF-NMFSSPJFSA-N

InChi Code

InChI=1S/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9)/i1D2,2D2,3D2

SMILES Code

NC(CN1C(C([2H])(C([2H])(C1([2H])[2H])[2H])[2H])=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 148.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kurian MA, Abela L. DNAJC6 Parkinson Disease. 2021 May 13. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. PMID: 33983693. 2: Sharif S, Guirguis A, Fergus S, Schifano F. The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. Brain Sci. 2021 Mar 10;11(3):355. doi: 10.3390/brainsci11030355. PMID: 33802176; PMCID: PMC8000838. 3: Tran QK, Bzhilyanskaya V, Afridi LZ, Ahmad M, Palmer J, Rehan MA, Raffman A, Rashid A, Menne A, Pourmand A. Preventing seizure occurrence following spontaneous intracerebral haemorrhage: A systematic review and meta-analysis of seizure prophylaxis. Seizure. 2021 Apr;87:46-55. doi: 10.1016/j.seizure.2021.02.029. Epub 2021 Mar 1. PMID: 33713891. 4: Sutherland A, Meldon C, Harrison T, Miller M. Subcutaneous Levetiracetam for the Management of Seizures at the End of Life: An Audit and Updated Literature Review. J Palliat Med. 2021 Jul;24(7):976-981. doi: 10.1089/jpm.2020.0414. Epub 2020 Dec 1. PMID: 33296254. 5: Factor SA. Management of Tardive Syndrome: Medications and Surgical Treatments. Neurotherapeutics. 2020 Oct;17(4):1694-1712. doi: 10.1007/s13311-020-00898-3. PMID: 32720245; PMCID: PMC7851276. 6: Fessel J. Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs. Alzheimers Dement (N Y). 2019 Nov 16;5:780-788. doi: 10.1016/j.trci.2019.09.019. PMID: 31763432; PMCID: PMC6861553. 7: Mohamudally A, Clark K. Levetiracetam at the End of Life: A Case Report and Discussion. J Palliat Med. 2020 Jul;23(7):995-997. doi: 10.1089/jpm.2019.0347. Epub 2019 Oct 11. PMID: 31603723. 8: Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019 Oct;49(14):2307-2319. doi: 10.1017/S0033291719001995. Epub 2019 Aug 23. PMID: 31439071; PMCID: PMC6763537. 9: Wilms W, Woźniak-Karczewska M, Corvini PF, Chrzanowski Ł. Nootropic drugs: Methylphenidate, modafinil and piracetam - Population use trends, occurrence in the environment, ecotoxicity and removal methods - A review. Chemosphere. 2019 Oct;233:771-785. doi: 10.1016/j.chemosphere.2019.06.016. Epub 2019 Jun 4. PMID: 31200137. 10: Finsterer J. Pharmacotherapeutic management of epilepsy in MERRF syndrome. Expert Opin Pharmacother. 2019 Jul;20(10):1289-1297. doi: 10.1080/14656566.2019.1609941. Epub 2019 May 7. PMID: 31063406. 11: Gudasheva TA, Ostrovskaya RU, Seredenin SB. Novel Technologies for Dipeptide Drugs Design and their Implantation. Curr Pharm Des. 2018;24(26):3020-3027. doi: 10.2174/1381612824666181008105641. PMID: 30295186; PMCID: PMC6302556. 12: Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit. 2018 Oct;40(5):526-548. doi: 10.1097/FTD.0000000000000546. PMID: 29957667. 13: Greenhalgh J, Weston J, Dundar Y, Nevitt SJ, Marson AG. Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Cochrane Database Syst Rev. 2018 May 23;5(5):CD007286. doi: 10.1002/14651858.CD007286.pub4. Update in: Cochrane Database Syst Rev. 2020 Apr 28;4:CD007286. PMID: 29791030; PMCID: PMC6494638. 14: Watkins AK, Gee ME, Brown JN. Efficacy and safety of levetiracetam for migraine prophylaxis: A systematic review. J Clin Pharm Ther. 2018 Aug;43(4):467-475. doi: 10.1111/jcpt.12715. Epub 2018 May 20. PMID: 29781197. 15: Liu S, Wang L, Cai XT, Zhou H, Yu D, Wang Z. Therapeutic benefits of ACTH and levetiracetam in STXBP1 encephalopathy with a de novo mutation: A case report and literature review. Medicine (Baltimore). 2018 May;97(18):e0663. doi: 10.1097/MD.0000000000010663. PMID: 29718889; PMCID: PMC6392729. 16: Bakr A, Belli A. A systematic review of levetiracetam versus phenytoin in the prevention of late post-traumatic seizures and survey of UK neurosurgical prescribing practice of antiepileptic medication in acute traumatic brain injury. Br J Neurosurg. 2018 Jun;32(3):237-244. doi: 10.1080/02688697.2018.1464118. Epub 2018 Apr 24. PMID: 29688078. 17: Zaccara G, Giorgi FS, Amantini A, Giannasi G, Campostrini R, Giovannelli F, Paganini M, Nazerian P; Tuscany study group on seizures in the emergency department and status epilepticus in adults. Why we prefer levetiracetam over phenytoin for treatment of status epilepticus. Acta Neurol Scand. 2018 Jun;137(6):618-622. doi: 10.1111/ane.12928. Epub 2018 Apr 6. PMID: 29624640. 18: Jamroz W, Kurek M, Lyszczarz E, Brniak W, Jachowicz R. PRINTING TECHNIQUES: RECENT DEVELOPMENTS IN PHARMACEUTICAL TECHNOLOGY. Acta Pol Pharm. 2017 May;74(3):753-763. PMID: 29513944. 19: Stockburger C, Eckert S, Eckert GP, Friedland K, Müller WE. Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer's Disease. J Alzheimers Dis. 2018;64(s1):S455-S467. doi: 10.3233/JAD-179915. PMID: 29504539. 20: Łukawski K, Andres-Mach M, Czuczwar M, Łuszczki JJ, Kruszyński K, Czuczwar SJ. Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies. Pharmacol Rep. 2018 Apr;70(2):284-293. doi: 10.1016/j.pharep.2017.07.012. Epub 2017 Jul 16. PMID: 29477036.